reuse retatrutide Unlicensed weight-loss drugs marketed on social media as 'prizes' | Weight-loss drugs Retatrutide vs. semaglutide: A head-to-head

Peer review Peer review information Nature Reviews Endocrinology thanks Geltrude Mingrone, Alex Miras, Pirjo Nuutila and Antonio Ettore Pontiroli for their contribution to the peer review of this work

The lack of in-depth investigation into redox homeostasis regulation limits the appropriate clinical application in multiple aspects with medication dose range as the main concern

Following Mondays clinical defeat by Eli Lilly, Novo Nordisk cut the 2027 list prices for its three GLP-1 medicines by as much as 50%, while boasting Phase 2 data for its invesigational triple-G agonist

1 2 3 4 5 How do you prefer to take your medication